Literature DB >> 16230278

[Arginine and statins: relationship between the nitric oxide pathway and the atherosclerosis development].

C Rasmusen1, L Cynober, R Couderc.   

Abstract

Arginine, a semi-essential amino acid, plays a major nutritional and metabolic role. In particular, arginine is the precursor of nitric oxide which is involved in the endothelial function. Several factors, such as hypercholesterolemia, diabetes, ageing and hypertension are established risk factors for atherosclerosis, in particular by decreasing the availability of nitric oxide. Thus, endothelial nitric oxide synthase has a pivotal role against atherosclerosis. A suitable amount of cofactor and a sufficient intake of arginine have been shown to modulate nitric oxide-induced vasodilatation: despite the fact that the intracellular concentration of arginine is well above the Km of endothelial nitric oxide synthase, an arginine supplemented-diet is effective in increasing the production of nitric oxide. Several mechanisms have been proposed to explain this "arginine paradox": co-localization of the arginine transporter with endothelial nitric oxide synthase, intracellular arginine regeneration from citrulline, balance between endothelial arginase and nitric oxide synthase. Statins which are HMG-CoA reductase inhibitors inhibit the synthesis of mevalonate, and thus that of cholesterol. In addition, statins increase the stabilization of endothelial nitric oxide synthase mRNA. The co-operation between cholesterol synthesis and the upregulation of caveolin-1 on the one hand, and the activation of endothelial nitric oxide synthase on the other hand, is very tight. A depletion of cholesterol in the caveolae induces a decrease in caveolin-1 at the cell surface allowing NOS activation. Thus statins improve nitric oxide production and vasodilatation. In a recent work in the hypercholesterolemic Watanabe rabbit, we have demonstrated that the combination of arginine with a statin, namely atorvastatin, significantly hinders the spreading of atherosclerotic plaques as compared with monotherapies. Such association of a nutriment and a drug open a new area of therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230278

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  3 in total

1.  Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.

Authors:  Mohamed Mahmoud El-Seweidy; Mervat El-Sayed Asker; Sameih Ibrahim Eldahmy; Hebatallah Husseini Atteia; Mohamed Ahmed Abdallah
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  Improving Total-Cholesterol/HDL-Cholesterol Ratio Results in an Endothelial Dysfunction Recovery in Peripheral Artery Disease Patients.

Authors:  Silvia Bleda; Joaquín de Haro; César Varela; Leticia Esparza; Javier Rodriguez; Francisco Acin
Journal:  Cholesterol       Date:  2012-09-25

Review 3.  Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Saeideh Hajighasemi; Maciej Banach; Peter E Penson; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Clin Med       Date:  2019-11-22       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.